Home › Hidradenitis Suppurativa › Massachusetts
Hidradenitis Suppurativa clinical trials in Massachusetts
10 studies for Hidradenitis Suppurativa are looking for participants at sites in Massachusetts.
Cities in Massachusetts
Safety and Efficacy of Soquelitinib in Adults With Hidradenitis Suppurativa
- Clinical Site 3, Boston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07828860A Study to Investigate Efficacy and Safety With SAR445399 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
- Beth Israel Deaconess Medical Center - Boston- Site Number : 8400001, Boston
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07225569A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)
- Up0122 104, Boston
RecruitingPhase 1
Ages 18 and older · Women · Updated Sep 18, 2026 · NCT06888193Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib
- Investigative Site US030, Boston
- Investigative Site US048, Brighton
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 15, 2026 · NCT06855498Targeting Nociceptors in Hidradenitis Suppurativa
- University of Massachusetts Chan Medical School, Worcester
RecruitingObservational study
Ages 18 to 75 · All sexes · Updated Sep 10, 2026 · NCT05403710Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
- Boston Childrens Hospital, Boston
RecruitingPhase 2
Ages 12 to 17 · All sexes · Updated Aug 6, 2026 · NCT07213973A Study to Assess NAV-240 in Adult Participants With Hidradenitis Suppurativa
- Beth Israel Deaconess Medical Center, Boston
RecruitingPhase 2
Ages 18 to 70 · All sexes · Updated Jul 22, 2026 · NCT07384975The Safety and Efficacy of Roflumilast Foam in HS
- Beth Israel Deaconess Medical Center, Boston
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jul 9, 2026 · NCT07263230A Long-Term Follow-Up Observational Study to Evaluate Safety in Subjects Who Have Received a Gene-Modified Regulatory T Cell (Treg) Therapeutic
- Tufts University, Boston
- Massachusetts General Hospital, Boston
- Brigham and Women's Hospital, Boston
RecruitingObservational study
Ages 18 to 71 · All sexes · Updated Apr 16, 2026 · NCT07123038A Study of Zasocitinib in Adults With Hidradenitis Suppurativa
- Beth Israel Deaconess Medical Center, Boston
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Mar 6, 2026 · NCT07244263From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.